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I I 
TRICUSPID VALVE 
REPLACEMENT: 
POSTOPERATIVE AND 
LONG-TERM RESULTS 
A series of 146 consecutive patients who underwent ricuspid valve replace- 
ment at the University Brugmann Hospital between 1967 and 1987 was 
reviewed. Mean age at operation was 51.4 years (-+12.1 years). Different ypes 
of prostheses were implanted including porcine and bovine pericardial bio- 
prostheses and older and bileaflet mechanical valves. Most patients were 
severely disabled by their cardiac disease before operation, with 30.1% in New 
York Heart Association funetional dass I I I  and 69.9% in class IV. Operative 
mortality and hospital mortality rates (30 days) were high (16.4%). Incremen- 
tal risk factors for hospital death included icterus (p < 0.005), preoperative 
hepatomegaly (p = 0.012), and New York Heart Association functional dass IV 
(p = 0.013). Multivariate analysis only selected preoperative icterus (p < 0.01) 
as being independently significantly related to hospital mortality. The hospital 
survivors were followed up for a median of 94 months. A complete follow-up 
was available for all patients except wo for 30 months or more. At 30 months 
the only two significant parameters were the type of myocardial protection (p = 
0.024) and the year of operation (before 1977 or after [precardioplegia era or 
after],p = 0.011). There were 70 late deaths during the entire follow-up period. 
The univariate (log-rank statistics) incremental risk factor for late death was 
the type of tricuspid prosthesis (Smeloff-Cutter and Kay-Shiley versus St. Jude 
Medical versus bioprosthesis) (p = 0.04). A trend was observed for the type of 
operative myocardial protection (normothermia and coronary perfusion) (p = 
0.06) and preoperative New York Heart Association functional class IV (p = 
0.055). Actuarial survival was 74% at 60 months and 23.4% at 180 months. 
Cumulative follow-up added up to 1015 patient-years. In a more detailed 
analysis of the effect on survival of the type of tricuspid prosthesis, a significant 
difference was observed between the bioprostheses and some older mechanical 
prostheses (Smeloff-Cutter and Kay-Shiley) (p = 0.04) but not between the 
bioprostheses and the bileaflet valves (p = 0.15). When the follow-up period 
was stratified according to less than 7 years and more than 7 years of follow-up, 
no difference was observed for the first period, but for the late follow-up the 
new mechanical prostheses did better than the bioprostheses (p = 0.05), 
suggesting a degradation of the bioprostheses after 7 years and favoring 
mechanical prostheses for those patients with a good long-term prognosis. 
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S ince the start of tricuspid valve replacements inthe early 1960s, nearly all types of prostheses 
have been used in the tricuspid position, with dif- 
ferent results. In the absence of severe structural 
damage of the native valve, repair or annuloplasty 
should always be attempted. 1 During the period of 
our study 173 tricuspid valve reconstructions were 
done at the same hospital. Nevertheless, nearly 45% 
of our patients with tricuspid valve disease required 
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Table I. Clinical features of the 146 patients 
undergoing TVR 
Clinical feature N % 
NYHA class 
III 44 30.1 
IV 102 69.9 
Rhythm 
Atrial flbrillation 122 83.5 
Sinus rl~tythm 22 15.1 
Unknown 2 1.4 
Hepatomegaly 80 54.8 
Icterus 31 21.2 
Peripheral edema 66 45.2 
Ascites 21 14.4 
Cyanosis 24 16.4 
Cardiothoracic ratio >0.5 143 97.9 
valve replacement, more frequently in the early 
years. We reviewed and analyzed the results in our 
146 patients with valve replacement to establish a 
strategy toward the optimal valve choice. As de- 
scribed by McGrath and colleagues, 2 bioprostheses 
in the tricuspid position perform well up to 10 years 
after implantation, but can show some structural 
deterioration, and this finding was even more pro- 
nounced in younger patients in other series. 3Good 
long-term results with bileafiet mechanical valves 
could alter our policy of using preferentially a large 
bioprosthesis in the tricuspid position. 
Patients and methods 
All 146 patients who underwent tricuspid valve replace- 
ment (TVR) at the University Brugmann Hospital be- 
tween 1967 and 1987 were included in the review. Our 
series included 32 male (21.9%) and 114 fernale (78.1%) 
patients with a rnean age of 51.4 years (range 15 to 71 
years, standard eviation 12.1). The clinical data of the 
patients in the TVR group are surnrnarized in Table I. 
Rheumatic heart disease was the most frequent cause and 
was present in 102 patients (69.9%). Ebstein's anomaly 
occurred in 4 (2.7%), endocarditis n 3 (2.1%), and in the 
rernaining 37 patients (25.3%) the disease proeess was 
considered to be functional. Eighty-eight (60.3%) patients 
had tricuspid valve regurgitation only, 4 had pure stenosis 
(2.7%), and 54 (37.0%) had a combination of both, as 
assessed clinieally, echoeardiographically, hemodynami- 
cally, and perioperatively. Most of our patients had an 
advanced stage of heart valve disease, with 44 patients 
(30.1%) in New York Heart Association (NYHA) func- 
tional cla~s III and 102 patients (69.9%) in class IV or 
higher. Agcites was present in 21 patients (14.4%), cyano- 
sis in 24 (16.4%), hepatomegaly in 80 (54.8%), edema in 
66 (45.2%), and icterus in 31 (21.2%). Concomitant 
cardiac procedures were necessary in 139 patients 
(95.2%), ~as shown in Table II. Moreover, 59 patients 
Table II. Associated cardiac procedures in 146 
patients undergoing TVR 
Procedures done N % 
MVR 93 63.6 
AVR, MVR 26 17.8 
AVR 2 1.3 
OMC 2 1.3 
MVR, aortic valve repair 1 0.7 
Thrombectomy left atrium 5 3.4 
Thrombectomy right atrium 1 0.7 
Mitral paravalvular leak closure 2 1.3 
Aortic paravalvular leak closure 1 0.7 
Atrial septum defect repair 3 2.0 
Ventricular septum defect repair 1 0.7 
Epicardial pacemaker 2 1.4 
Total 139 95.2 
MVR, Mitral valve r placement; AVR, aortic valve r placement; OMC, 
open mitral commissurotomy. 
Table III. Previous cardiac operations in 146 
patients undergoing TVR 
N % 
One procedure 
MVR 
CMC 
OMC 
AVR, MVR 
AVR 
OMC, tricuspid valve repair 
MVR, tricuspid valve r pair 
AVR, MVR, tricuspid valve repair 
AVR, MVR 
OMC, OTC 
Tricuspid valvectomy 
Atrial septum defect repair 
Pericardectomy 
Total 
Two procedures 
First 
CMC 
CMC 
AVR, MVR 
AVR, MVR 
MVR 
VSD repair 
Total 
13 8.9 
16 10.9 
12 8.2 
5 3.4 
2 1.4 
3 2.0 
2 1.4 
1 0.7 
1 0.7 
1 0.7 
1 0.7 
1 0.7 
1 0.7 
59 40.4 
Second 
CMC 1 0.7 
AVR, MVR, tricuspid 1 0.7 
valve repair 
AVR, MVR 1 0.7 
Paravalvular leak closure I 0.7 
Paravalvular leak closure 1 0.7 
Residual VSD closure 1 0.7 
6 4.1 
MVR, Mitral valve replacement; CMC, closed mitral commissurotomy; 
OMC, open mitral commissurotomy; AVR, atrial valve replacement; OTC, 
open tricuspid commissurotomy; VSD, ventricular septal defect. 
(40.4%) had undergone one previous cardiac operation 
and 6 had undergone two (4.1%), as shown in Table III. 
We used different ypes of prostheses in the tricuspid 
position: 69 bioprostheses (47.3%) and 77 mechanical 
valves (52.7%). During the 1960s and early 1970s, only 
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Table IV. Univariate analysis of clinical variables 
related to hospital mortality 
P 
Alive Dead Value 
Age (yr, mean _+ SD) 51.5 _+ 12.6 52.7 -+ 9.6 NS 
Sex 
Female 99 15 
Male 23 9 0.04 
Previous operation 
Absent 69 13 
Present 53 11 NS 
Rheumatic disease 
Absent 32 12 
Present 88 14 NS 
Tricuspid disease 
Regurgitation 71 17 
Stenosis 51 7 NS 
NYHA class 
III 42 2 
IV 80 22 0.013 
Ascites 
Absent 107 18 
Present 15 6 NS 
Cyanosis 
Absent 105 17 
Present 17 7 NS 
Icterus 
Absent 102 13 
Present 20 11 0.005 
Hepatomegaly 
Abseht 61 5 
Present 61 19 0.012 
Edema 
Absent 65 15 
Present 57 9 NS 
SD, Standard eviation; NS, not significant. 
old-style mechanical valves (27 Smeloff-Cutter,* 14 Kay- 
Shiley,'~ and 1 DeBakey~:) were available. Before 1977, 23 
Björk-Shiley'~ tilting-disc valves were implanted in the 
tricuspid position. Since 1975, porcine xenografts (31 
Carpentier-Edwards§ and 25 Hancockll) have been cur- 
rently used. Between 1979 and 1981, 12 St. Jude Medical¶ 
mechanical valves were inserted in the tricuspid position. 
FinaUy, some bovine pericardial bioprostheses (9 Carpen- 
tier-Edwards and 4 Mitroflow) were implanted between 
1978 and 1983. 
All operations were done through median sternotomy 
with the use of standard cardiopulmonary b pass (CPB). 
Before 1977, normothermic CPB with coronary peffusion 
and mild systemic hypothermia was used, whereas more 
* Cutter Biological, Berkeley, Calif, 
I Shiley, Inc., Irvine, Calif. 
:~ Surgitool, Inc., Pittsburgh, Pa. 
§ Baxter Healthcare Corp., Edwards Division, Santa Ana, Calif. 
II Johnson & Johnson Cardiovascular, Fdng of Prussia, Pa. 
¶ St. Jude Medical, Inc., St. Paul, Minn. 
recently moderate hypothermia and cold antegrade St. 
Thomas' Hospital cardioplegic solution has been used. 
Anticoagulation therapy with warfarin (Coumadin) was 
started on the first postoperative day and continued 
life-long in patients with mechanical valves or chronic 
atrial fibrillation; otherwise itwas stopped after 3 months. 
Several clinical parameters and surgical parameters were 
recorded retrospectively. 
Statistical analysis. Continuous variables are ex- 
pressed as mean and standard eviations. Variables en- 
tered into risk-factor analysis included age, gender, pre- 
vious operation, rheumatic disease, tricuspid disease, 
NYHA functional class, ascites, cyanosis, icterus, hepato- 
megaly, edema, duration of aortic clamping, duration of 
CPBs, myocardial protection, year of operation, and type 
of prosthesis. For statistical power considerations the 
types of tricuspid prostheses were grouped into three 
categories: bioprostheses, old mechanical prostheses, and 
new mechanical prostheses. Univariate comparisons be- 
tween the groups of survivors and nonsurvivors at30 days 
and 30 months after operation were done by Fisher's exact 
test and Student's t test. A stepwise multivariate logistic 
regression was used to identify a subset of independent 
variables predictive of hospital and 30-month mortality 
(Systat 5.2 statistical program, Systat, Inc., Evanston, 
Ill.). The level for entrance to or removal from the 
model was set at 0.05. Univariate analysis of survival 
curves was done by the log-rank test. 4 
Results 
Hospital mortality. Twenty-four patients died 
during hospitalization, yielding a hospital mortality 
rate of 16.4%. Cardiac failure was responsible in 11 
patients (45.8%), bleeding in 3 (12.5%), arrhythmias 
in 3 (12.5%), multiple organ failure in 2 (8.3%), 
respiratory insufficiency in 1 (4.2%), sepsis in 1 
(4.2%), and valvular thrombosis in 1 (4.2%); sudden 
death of unknown origin occurred in 2 patients 
(8.4%). Univariate analysis (Table IV) showed pres- 
ence of icterus (p = 0.005), presence of hepatomeg- 
aly (p = 0.012), NYHA class IV (p = 0.013), and 
male gender (p = 0.04) to be associated with 
hospital mortality. The cause (rheumatic or not) of 
the tricuspid valve disease and the pathologic on- 
dition of the tricuspid valve (regurgitant or not) 
showed no relation with the in-hospital outcome. 
Among the perioperative parameters no relation 
was found at all with early survival (Table V). 
Valve-related complications. Paravalvular leak- 
age developed in 4 patients (3.3%). Twice the 
tricuspid prosthesis was concerned: once in a 
Smeloff-Cutter and once in a Björk-Shiley valve. 
The first patient died without surgical intervention 
and the latter underwent successful replacement of
the affected prosthesis. Late endocarditis occurred 
in 3 patients (2.5%) 36, 54, and 96 months, respec- 
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tively, after operation. This involved 1 Carpentier- 
Edwards mitral prosthesis, 1 Kay-Shiley tricuspid 
prosthesis, and both mitral and tricuspid St. Jude 
Medical prostheses in the last patient. All patients 
were treated medically. The first 2 patients recov- 
ered and the latter died of a cerebrovascular acci- 
dent. Major anticoagulant-related h morrhage (ne- 
cessitating hospitalization and transfusion) occurred 
in 13 patients (10.7%). Four cases were fatal: 2 
digestive, 1 cerebral, and 1 posttraumatic. 
Reoperation and valve trombosis. Late tricuspid 
valve reoperation was required in 11 of the hospital 
survivors (9%) (Table VI). The mean interval to 
reoperation was 83.8 months (range 0.27 to 161 
months). Three patients did not survive reoperation 
(27.3%); orte died of cardiac failure, another of 
respiratory failure, and in the third patient he cause 
remains unknown. Prosthetic valve thrombosis oc- 
curred in 11 patients. Two cases of valve thrombosis 
on postoperative days 6 and 8 were fatal. Nine 
patients had late thrombosis from 5 to 132 months 
after primapj TVR. The types of prosthesis nvolved 
included 4 Smeloff-Cutter valves (3 in the tricuspid 
and 1 in the mitral position), 3Björk-Shiley valves (2 
in the tricuspid and 1 in the mitral and tricuspid 
positions), and 1 St. Jude Medical valve and 1 
Carpentier-Edwards valve in the tricuspid position. 
Of these 9 patients, 6 died before surgical interven- 
tion and the other 3 underwent successful replace- 
ment of the thrombosed prosthesis. Actuarial free- 
dom from death and reoperation with a tricuspid 
valve prosthesis i shown in Fig. 1 for the different 
valve types. 
Thirty-month mortality. A total of 120 hospital 
survivors were followed up for at least 30 months 
(this includes all patients except two, who were 
followed up for 27 and 29 months, respectively). An 
interim analysis at 30 months howed only a signif- 
icant different survival for the type of myocardial 
protection (hypothermia, 8 of 68 versus normother- 
mia, 13 of 43;p = 0.024) and the use of cardioplegia 
(before 1977, 18 of 65 versus after 1977, 5 of 55;p = 
0.011). A trend was also shown for NYHA func- 
tional class before operation (class III, 4 of 41 versus 
class IV, 19 of 79; p = 005) (Table VII). A multiva- 
riate logistic regression at 30 months selected the 
absence of myocardial protection and the presence 
of tricuspid valve stenosis as the two factors posi- 
tively and independently related to mortality (p = 
0.015 and p = 0.048, respectively). 
Late snrvival. Late death occurred in 70 of the 
122 hospital survivors of the original TVR (57.4%). 
Table V. Univariate analysis of perioperative 
variables related to hospital mortality 
P 
Alive Dead Value 
Aortic clamp time 66.2 _+ 32.5 68.2 _+ 36.1 NS 
(min) 
Duration of CPB 113 _+ 31.1 141.3 + 58.5 NS 
(min) 
Myocardial protection 
Normothermia 43 11 0.99 
Hypothermia 70 13 
Tricuspid prosthesis 
Old mechanical 33 9 0.49 
New mechanical 29 6 
Bioprosthesis 60 9 
NS, Not significant. 
Modes included cardiac failure in 25 patients 
(35.7%), sudden death in 10 (14.3%), neurologic 
events in 5 (7.1%), valvular thrombosis n 5 (7.1%), 
anticoagulant-related bl eding in 4 (5.7%), valvular 
prosthesis dysfunction i  3 (4.3%), infective ndo- 
carditis in 2 (2.8%), arrhythmia n i (1.4%), noncar- 
diac causes in 8 (11.4%), and unknown causes in 7 
(10.0%). Cumulative follow-up added up to 1015 
patient/years and the median survival time for hos- 
pital survivors was 116 months. Two patients were 
lost to follow-up (98.4% complete). The actuarial 
survival at 60 months remained 74.0% and de- 
creased at 180 months to 23.4% (Fig. 2). Of the 52 
long-term survivors, 11 (21.2%) are in NYHA func- 
tional class I, 32 (61.5%) in class II, 6 (11.5%) in 
class III, and the remaining 3 (5.8%) in class IV. 
Thirty-nine patients (75%) have atrial fibrillation, 7 
have regular sinus rhythm (13.5%), 5 had a pace- 
maker implanted (9.6%), and in 1 patient the 
rhythm remains uncertain (1.9%). Univariate anal- 
ysis (log-rank statistics) revealed the type of tricus- 
pid prosthesis (Smeloff-Cutter and Kay-Shiley ver- 
sus St. Jude Medical and bioprosthesis) (p = 0.04) 
as an incremental risk factor for late death. A trend 
was observed for the type of operative myocardial 
protection (normothermia and coronary perfusion) 
(p = 0.06) and preoperative NYHA functional class 
IV (p < 0.06). A more detailed analysis of the effect 
on survival of the type of tricuspid prosthesis 
showed asignificant difference between the biopros- 
thesis and the older mechanical prostheses 
(Smeloff-Cutter and Kay-Shiley) (p = 0.04) but not 
between the bioprosthesis and the new prosthesis 
(p = 0.15) (Fig. 1). When the follow-up period was 
stratified according to less than 7 years and 7 or 
more years of follow-up, no significant difference 
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Fig. 1. Actuarial freedom frorn death and reoperation with tricuspid prosthesis for different valve types. 
Bio, Bioprosthesis. 
Table VI. Reoperations 
Reason for Interval to Reoperation New tricuspid 
Original va lve  malfunction reoperation procedure prosthesis Status 
Smeloff-Cutter Pannus 83 mo TVR St. Jude Medical Alive 
Pannus 89 mo TVR St. Jude Medical AIive 
Thrombus 96 mo TVR Carpentier-Edwards Died 
Björk-Shiley Thrombus 16 mo TVR Smeloff-Cutter Alive 
Pannus 161 mo TVR Carpentier-Edwards Alive 
Thrombus 25 mo TVR, MVR Smeloff-Cutter Alive 
Thrombus 8 days TVR Smeloff-Cutter Died 
Kay-Shiley Pannus 45 mo TVR Smeloff-Cutter Alive 
Carpentier-Edwards PVF 133 mo TVR Carpentier-Edwards Alive 
PVF 142 mo TVR None Died 
Thrombus i32 mo TVR, MVR, AVR Carpentier-Edwards Alive 
MVR, Mitral valve replacement; PVF, primary valve failure; AVR, aortic valve replacement. 
was observed for the first period but for the late 
follow-up the new mechanical prosthesis did better 
than the bioprosthesis (p = 0.05). A stepwise mul- 
tiple logistic regression test selected the presence of 
icterus as the sole independent predictor of late 
death (p < 0.01). 
Diseussion 
The operative mortality rate of 16.4% in our 
series is comparable with those in literature reports, 
which fange from less than 10% to more than 50% 
for both isolated and combined TVR. 5"19 A reduc- 
tion in mortality rate in the more recent era was also 
observed by Livi and colleagues 2° and related to 
improvement of perioperative myocardial protec- 
tion and postoperative management. Almost half of 
our early deaths were caused by cardiac failure 
related to severe depression of myocardial function, 
which was especially noticed in the precardioplegia 
group as reported in most series. 6-8' 11, 14, 16, 18-21 
This was also confirmed indirectly in our series by 
the significant relation between the year of interven- 
tion and the survival (before 1977 versus after 1977). 
A number of preoperative variables were identified 
as univariate predietors of high risk for hospital 
death after TVR: male gender, NYHA functional 
class IV, hepatomegaly, and icterus. Poor survival in 
men, also detected by other authors, remains unex- 
plained.19, 22 The increased early risk for TVR in 
patients with advanced functional disability has been 
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Fig. 2. Actuarial survival curves according to type of prosthesis. Biß Bioprosthesis. 
documented in some reports. 9'18-20, 22 Preoperative 
hepatomegaly and icterus likely represent hepatic 
congestion resulting from severe failure of the right 
side of the heart and have been associated with high 
early mortality rates. 19' 22 Age (yr, mean -+ SD) 
Late death occurred in 57% of the hospital survi- Sex 
vors of the original TVR. More than orte third of Female 79 
Male 18 
these patients died of cardiac failure, which suggests Rheumatic d sease 
progression of cardiomyopathy despite successful Absent 16 
surgical valve replacement. 9' 17, is Significant univa- Present 80 
riate risk factors for late death were the use of a NYHA 
Smeloff-Cutter or Kay-Shiley tricuspid prosthesis, III 37 
IV 60 
myocardial protection by normothermia and coro- Ascites 
nary perfusion, and preoperative NYHA functional Absent 85 
class IV. Intraoperative myocardial protection has present 12 
been rep0rted to influence operative mortality, but Cyanosis 
not late deathY Advanced functional disability Absent 84 
Present 13 
seems to have an ominous influence not only on Icterus 
early but also on long-term results of TVR. 9' 19, 21 Absent 83 
The higher prevalence of tricuspid valve thrombosis Present 14 
in older mechanical valves has been confirmed by Hepatomegaly 
several authors. 6'9, 16, 21, 23 Likewise, a low preva- Absent 48 
' Present 49 
lence of Valve-related thromboembolism with the St. Year of operation 
Jude Medical valve in patients with correctly regu- Before 1977 47 
lated an~icoagulation therapy has been report- After 1977 51 
ed. 24-26 The long-term results, 14 years after implan- Myocardial protection 
Normothermia 60 
tation of the bileaflet valve, equal at approximately Hypothermia 30 
8 years ~the good score of the bioprosthesis, to Tricuspid prosthesis 
improve !the late results, but this requires further Old mechanical 24 
follow-ul5. On the other hand, degeneration of the New mechanical 22 
bioprosti~esis in the tricuspid position is exceptional Bioprosthesis 51 
during the first 10 years and becomes more pro- 
Table VII. Univariate analysis of variables related 
to 30-month mortality 
P 
Alive Dead Value 
50.8 -+ 11.9 52.2 -+ 15.0 NS 
18 
5 NS 
3 
19 NS 
4 
19 0.05 
21 
2 NS 
20 
3 NS 
18 
5 NS 
12 
11 NS 
18 
5 0.01 
13 
8 0.02 
NS 
SD, Standard eviation; NS, not significant. 
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nounced more than 10 years after initial implanta- 
tion, especially in children. 2' 3, 27, 28 In our series, two 
cases of primary valve failure necessitated replace- 
ment, both more than 10 years after initial implan- 
tation. Other valve-related complications uch as 
endocarditis and paravalvular leakage were rare, 
regardless of the type of tricuspid prosthesis. 
In conclusion, TVR carries a high operative risk 
and low likelihood of long-term survival, both influ- 
enced by preoperative and perioperative variables. 
Mechanical disc or ball valves in the tricuspid posi- 
tion are prone to dysfunction by pannus formation 
or thrombosis. 22'29'3° Moreover, Smeloff-Cutter 
and Kay-Shiley prostheses are incremental risk fac- 
tors for late death. Because bioprostheses in the 
tricuspid position have a low risk of valve-related 
events, we preferred a large-sized bioprosthesis 
when TVR was mandatory, although the confirma- 
tion of better long-term results (14 years) of the St. 
Jude Medical valves altered our valve choice in 
some particular young patients with a good long- 
term prognosis. 
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